companydirectorylist.com  Global Business Directory e directory aziendali
Ricerca Società , Società , Industria :


elenchi dei paesi
USA Azienda Directories
Canada Business Elenchi
Australia Directories
Francia Impresa di elenchi
Italy Azienda Elenchi
Spagna Azienda Directories
Svizzera affari Elenchi
Austria Società Elenchi
Belgio Directories
Hong Kong Azienda Elenchi
Cina Business Elenchi
Taiwan Società Elenchi
Emirati Arabi Uniti Società Elenchi


settore Cataloghi
USA Industria Directories












USA-UT-DEARBORN Azienda Directories

Liste d'affari ed elenchi di società:
CITISALES REALTY & DEVELOPMENT
Indirizzo commerciale:  2505 W 500 N,DEARBORN,UT,USA
CAP:  84014
Numero di telefono :  8014890989 (+1-801-489-0989)
Numero di Fax :  8013787315 (+1-801-378-7315)
Sito web:  bl-appraisalscom, utahappraisalscom
Email:  
USA SIC Codice:  653118
USA SIC Catalog:  Real Estate

Show 1-1 record,Total 1 record










Azienda News:
  • Medications for Eosinophilic Esophagitis - WebMD
    There are many medications for eosinophilic esophagitis Proton pump inhibitors, steroids, or a new drug, Dupixent, can all help you find relief
  • List of 9 Eosinophilic Esophagitis Medications Compared
    Drugs used to treat Eosinophilic Esophagitis The medications listed below are related to or used in the treatment of this condition Select drug class All drug classes Inhaled corticosteroids (6) Glucocorticoids (2) Interleukin inhibitors (2)
  • Common Medications for Eosinophilic Esophagitis (EoE)
    Common Medications for Eosinophilic Esophagitis (EoE) Subject: This sheet gives a brief summary of the types of medications used to treat Eosinophilic Esophagitis (EoE) It explains how they re given and the benefits of each Please talk about specific medications with your child s doctor Keywords: Medications, Eosinophilic Esophagitis Created
  • Management of eosinophilic esophagitis (EoE) - American . . .
    9 In patients with EoE, AGA JTF recommends using anti–IL-5 therapy for EoE only in the context of a clinical trial 10 In patients with EoE, AGA JTF recommends using anti-IL-13 or anti-IL-4 receptor α therapy for EoE only in the context of a clinical trial 11 In patients with EoE, AGA JTF suggests against the use of anti-IgE therapy for
  • Management of Eosinophilic Esophagitis - American Academy of . . .
    The US Food and Drug Administration (FDA) approved the first oral therapy for EoE in 2024 Eohilia (budesonide oral suspension) is approved for patients 11 years and older No mixing is required for this medication, which improves standardization of the dose Additional options (off-label) are Budesonide (swallowed slurry)




Annuari commerciali , directory aziendali
Annuari commerciali , directory aziendali copyright ©2005-2012 
disclaimer